Fig. 7

The combination of metabolic therapy and Sting agonists can enhance the anti-tumor effect. Schematic of treatment on a Hepa1–6 tumor model (a); Mouse body weight during the administration of different treatment protocols (b); Tumor volume variation during the administration of different treatment protocols (c); Weight of different resected tumors on day 18 (d); Tumor tissue section analysis of tumor sections by H&E staining, CD8⁺ T cells, TUNEL assays and Ki67 staining (e) (scale bar: 100 µm). The flow cytometry analysis of CD8⁺ T cells (f–h)